Takeda Pharmaceutical Co. said Tuesday the U.S. Food and Drug Administration has approved the sale of its new Actoplus Met drug for diabetes.
The new tablets combine Takeda's key diabetes drub Actos and another diabetes drug, Metformin, the top Japanese drug maker said.
Takeda Global Research & Development Center Inc., Takeda's U.S. research and development unit, filed for the approval. The U.S. unit, Takeda Pharmaceuticals North America Inc., will launch the product in October, it said.